FDA label 87F87FD3-7862-CB66-078F-2C076ED7E8A4

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
07568921-2ee9-42db-b9f1-e20e3749979c
SPL ID
87F87FD3-7862-CB66-078F-2C076ED7E8A4
Version
1
Effective date
2007-03-30
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:23:58

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Warnings BETA-BLOCKER WITHDRAWAL Nicardipine is not a beta-blocker and therefore gives no protection against the dangers of abrupt beta-blocker withdrawal; any such withdrawal should be by gradual reduction of dose of beta-blocker. RAPID DECREASES IN BLOOD PRESSURE No clinical events have been reported suggestive of a too rapid decrease in blood pressure with Cardene I.V. However, as with any antihypertensive agent, blood pressure lowering should be accomplished over as long a time as is compatible with the patient’s clinical status. USE IN PATIENTS WITH ANGINA Increases in frequency, duration, or severity of angina have been seen in chronic oral therapy with Cardene capsules. Induction or exacerbation of angina has been seen in less than 1% of coronary artery disease patients treated with Cardene I.V. The mechanism of this effect has not been established. USE IN PATIENTS WITH CONGESTIVE HEART FAILURE Cardene I.V. reduced afterload without impairing myocardial contractility in preliminary hemodynamic studies of CHF patients. However, in vitro and in some patients, a negative inotropic effect has been observed. Therefore, caution should be exercised when using Cardene I.V., particularly in combination with a beta-blocker, in patients with CHF or significant left ventricular dysfunction. USE IN PATIENTS WITH PHEOCHROMOCYTOMA Only limited clinical experience exists in use of Cardene I.V. for patients with hypertension associated with pheochromocytoma. Caution should therefore be exercised when using the drug in these patients. PERIPHERAL VEIN INFUSION SITE To minimize the risk of peripheral venous irritation, it is recommended that the site of infusion of Cardene I.V. be changed every 12 hours.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.